FDA approves first mRNA flu vaccine from Moderna.
Despite the preferences of some, Moderna announced that after years of work, mFLUSIVA (mRNA-1010) has been approved for use in adults aged 50 to 64, with an accelerated approval for adults 65 and up as they wait for the results of a follow-up study. While Moderna plans to roll it out by this fall, the WSJ notes it’s still unclear what RFK Jr.‘s vaccine recommendation panel will say about this use of the Nobel Prize-winning approach. [Link: F.D.A. Approves Moderna’s mRNA Flu Vaccine | https://www.nytimes.com/2026/08/05/health/mrna-flu-vaccine-moderna.html? | The New York Times]
Despite the preferences of some, Moderna announced that after years of work, mFLUSIVA (mRNA-1010) has been approved for use in adults aged 50 to 64, with an accelerated approval for adults 65 and up as they wait for the results of a follow-up study. While Moderna plans to roll it out by this fall, the WSJ notes it’s still unclear what RFK Jr.‘s vaccine recommendation panel will say about this use of the Nobel Prize-winning approach. [Link: F.D.A. Approves Moderna’s mRNA Flu Vaccine | | The New York Times]
Gathered from external sources. Rights to this text belong to whoever originally published it.